PMID: 6161320Jan 1, 1981Paper

Deprenyl in Parkinson disease

Neurology
T EislerD B Calne

Abstract

(-)Deprenyl, a specific monoamine oxidase subtype B inhibitor (MAOI-B), has been reported to be a safe and valuable adjunct to conventional treatment of parkinsonism. A double-blind, clinical comparison of (-)deprenyl with placebo was undertaken in 11 parkinsonian patients; the efficacy of 10 mg daily was studied over 4 weeks. In four cases the clinical score for parkinsonian deficits improved during deprenyl therapy, and in five it deteriorated; there was no change in one patient. Two subjects failed to complete the study. (-)Deprenyl induced euphoria and insomnia. It was concluded that any advantages deriving from the use of (-)deprenyl in parkinsonism are limited, and probably dominated by its elevation of mood. Biochemical analysis failed to reveal any significant increase in platelet or plasma catecholamine concentrations during deprenyl therapy. There was, however, a significant decrease in plasma epinephrine (p < 0.05) and platelet MAO activity (p < 0.005).

Citations

Mar 26, 1999·Movement Disorders : Official Journal of the Movement Disorder Society·A ChurchyardA J Lees
Jan 1, 1985·Psychopharmacology·T SunderlandD L Murphy
May 1, 1985·Biulleten' eksperimental'noĭ biologii i meditsiny·I V VerevkinaM D Mashkovskiĭ
Jun 1, 1985·Italian Journal of Neurological Sciences·P GiovanniniT Caraceni
Jan 1, 1993·Journal of Neural Transmission. Parkinson's Disease and Dementia Section·E H HeinonenM Scheinin
Jan 21, 1993·The New England Journal of Medicine·UNKNOWN Parkinson Study Group
Apr 1, 1996·Progress in Neuro-psychopharmacology & Biological Psychiatry·E HeadN W Milgram
Jan 1, 1991·Acta Neurologica Scandinavica. Supplementum·A J Lees
Jan 1, 1991·Acta Neurologica Scandinavica. Supplementum·A Lieberman, E Fazzini
Feb 3, 2000·Mechanisms of Ageing and Development·W Maruyama, M Naoi
Nov 1, 1992·Pharmacology, Biochemistry, and Behavior·E Head, N W Milgram
Jan 1, 1987·Pharmacology & Therapeutics·A E Lang
Dec 1, 1991·The American Journal of the Medical Sciences·D W Robin
May 11, 1992·Annals of the New York Academy of Sciences·I Shoulson
Jan 1, 1989·Acta Neurologica Scandinavica. Supplementum·P F Teychenne, S Parker
Apr 1, 1990·Acta Neurologica Scandinavica·H Teräväinen
Nov 16, 1989·The New England Journal of Medicine·UNKNOWN Parkinson Study Group
Mar 1, 1982·Journal of Neurology, Neurosurgery, and Psychiatry·R J AbbottS R Nahorski
Sep 1, 1990·Journal of Neurology, Neurosurgery, and Psychiatry·J J Askenasy, M D Yahr
Jun 1, 1985·Acta Neurologica Scandinavica·P BrodersenA Stigård
Mar 28, 1998·Acta Neurologica Scandinavica·A CharlettS M Dobbs
Feb 1, 1992·The Annals of Pharmacotherapy·D S CollierR W Fincham
Mar 1, 1993·Acta Neurologica Scandinavica·J J Askenasy
Jan 1, 1989·Acta Neurologica Scandinavica. Supplementum·E H Heinonen, U K Rinne
Feb 1, 1984·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·A E Lang
Jan 1, 1991·DICP : the Annals of Pharmacotherapy·M A Fuller, S R Tolbert

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.